【3 月 13 日，高盛发表研报指出重要观点！】高盛称，2025 年中国医疗保健行业更趋向常态化，药企将逐步适应新常态，但行业难以从近年政策冲击中快速恢复并实现 V 型反弹。高盛认为生成式人工智能虽成热门话题，但短期内对医药行业影响不显著，未来或有更多颠覆性科技重塑制药行业。基于行业发展趋势，高盛将所覆盖的中国医疗保健企业目标价下调 8%至上调 13%，对翰森制药等持“买入”评级，对复星医药等予“...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.